
GENB Stock Forecast & Price Target
GENB Analyst Ratings
Bulls say
Generate Biomedicines is poised for success with their innovative AI technology and promising product candidates in development. However, investors should carefully consider the risks before investing in this company.
Bears say
Generate Biomedicines is a clinical-stage company that has not yet generated any revenue, but has a projected enterprise value of ~$4.2B, with a primary focus on their lead candidate GB-0895 in severe asthma with an expected launch year of 2029. However, its single operating segment and concentration in one Phase 3 asset, as well as the still-evolving regulatory process for AI-driven drug development, pose potential risks to the company's future success and profitability. Payers may also be resistant to paying a premium for less frequent dosing, potentially hindering the commercial potential of GB-0895.
This aggregate rating is based on analysts' research of Generate Biomedicines Inc and is not a guaranteed prediction by Public.com or investment advice.
GENB Analyst Forecast & Price Prediction
Start investing in GENB
Order type
Buy in
Order amount
Est. shares
0 shares